太龙药业：上半年净利润1934.66万元，同比下降27.32%

Core Viewpoint - Tai Long Pharmaceutical (600222) reported a decline in both revenue and net profit for the first half of 2025, indicating challenges in its drug formulation business and increased production costs [1] Financial Performance - The company achieved a revenue of 762 million yuan, a year-on-year decrease of 17.77% [1] - The net profit attributable to shareholders was 19.35 million yuan, down 27.32% year-on-year [1] - Basic earnings per share were reported at 0.035 yuan [1] Business Operations - The decline in sales was attributed to the company's main products participating in the national Chinese medicine procurement, with uneven progress in regulatory approvals across provinces [1] - The decrease in sales led to unbalanced production, resulting in increased unit production costs and a decline in gross profit margin [1] - The rise in income tax expenses and changes in minority shareholder profits also contributed to the year-on-year decline in net profit [1]